Physician_Profile_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
117286,"Takeda Development Center Americas, Inc.",IL,100000000338,9644.49,08/22/2013,"In-kind items and services",106110961,Uloric,"","Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia","",""
117286,"Takeda Development Center Americas, Inc.",IL,100000000338,514.65,09/25/2013,"Cash or cash equivalent",106111712,Uloric,"","Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia","",""
117286,"Takeda Development Center Americas, Inc.",IL,100000000338,187.50,08/26/2013,"Cash or cash equivalent",106111715,Uloric,"","Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia","",""
117286,"Takeda Development Center Americas, Inc.",IL,100000000338,109.50,08/26/2013,"Cash or cash equivalent",106111714,Uloric,"","Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia","",""
117286,"Takeda Development Center Americas, Inc.",IL,100000000338,93.75,09/25/2013,"Cash or cash equivalent",106111713,Uloric,"","Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia","",""
117286,"Takeda Development Center Americas, Inc.",IL,100000000338,21.90,10/30/2013,"Cash or cash equivalent",106111707,Uloric,"","Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia","",""
117286,"Takeda Development Center Americas, Inc.",IL,100000000338,21.90,12/22/2013,"Cash or cash equivalent",106111711,Uloric,"","Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia","",""
